Acambis is putting its universal vaccine approach to influenza to the test as it launches a Phase I trial for ACAM-FLU-A, a universal therapy for all type "A" strains of the influenza virus. Researchers are looking for both efficacy as well as safety data by around the end of the year. The vaccine has potential as a therapy for use against a pandemic flu as well as seasonal flu. Pandemics are typically triggered by an "A" strain flu while seasonal flus are both "A" and "B" strains.
- read the report on Acambis from Hemscott